The trial was a Phase 2, double-blind, placebo-controlled randomized clinical trial with 225 participants that defined heart failure as LVEF< 40% and iron deficiency as serum ferritin level between 15-100 ng/ml or serum ferritin 101-299 ng/ml with transferrin saturation (TSAT) <20% [46]. The gene discussed is TF; the disease is heart failure.